Linezolid Adjunct Treatment for NTM Infections in Adult-Onset Immunodeficiency, 2017-2022

40 adult patients with nontuberculous mycobacterial diseases and anti-interferon gamma autoantibodies were prospectively studied from December 2017 to April 2022. The dataset likely contains records on a nine-month oral linezolid regimen's efficacy and tolerability, including relapse rates and adverse events. It was authored by Pakpoom Phoompoung and shared under a CC-BY-4.0 license.

Use Cases

• Modeling treatment failure risk based on patient outcomes and adverse event profiles mentioned in the description
• Analyzing the relationship between dose modifications and treatment efficacy for adjunctive antibiotic therapies
• Studying the incidence and types of adverse events like anemia and peripheral neuropathy in a specific immunodeficient cohort

Strengths

• Prospective cohort study design with a defined time range from December 2017 to April 2022
• Includes specific outcome metrics: 22.5% cumulative relapse rate and 15.0% treatment failure rate at nine months
• Reports detailed adverse event data, with 24 patients (60%) experiencing 31 total events

Limitations

• Row count and column-level documentation are unknown, which may limit suitability assessment
• The dataset is very small at 128.2 KB, indicating limited scope and sample size of 40 patients
• Data is provided in DOC/DOCX formats, which may require parsing to extract structured information

Provenance

Source

figshare

Collection Method

Prospective cohort study

Time Range

December 2017 to April 2022

Freshness

Last updated 2026-05-19 07:07:34; freshness should be verified